Skip to main content
. Author manuscript; available in PMC: 2016 Apr 1.
Published in final edited form as: Lab Invest. 2015 Jul 6;95(10):1145–1156. doi: 10.1038/labinvest.2015.77

Figure 1. Galectin 3−/− mice exhibit decreased tumor burden compared to the wild type mice.

Figure 1

Wild type and galectin 3−/− mice were injected with DEN at 4 weeks of age to induce HCC. After 52 weeks, the mice were injected via tail vein with 200μl of the contrast agent Fenestra LC and subjected to Micro-CT scan. The tumor size was assessed by volumetric analysis (A). The HCC on the CT is depicted as large hypodense areas (arrows) in the wild type mouse, (coronal view, a; and horizontal view, c). In the galectin3−/− mice smaller tumors were seen (b and d, arrowhead). By volumetric analysis, in the galectin 3−/− mice the tumor burden was significantly lower. (B, **p<0.01, N=5). The liver tissues from these mice were processed for immunohistochemistry to detect reticulin (C, a and b) and glypican 3 (C, c and d). Both wt and galectin 3−/− livers showed reduced reticulin and they were positive for glypican 3. This confirmed the presence of HCC in the mice. Bar=100 μm